Mymetics Corporation is a global leader in the development of virosome-based vaccines and immunotherapies for infectious and life-disabling diseases. With over 30 years of experience and a strong focus on scientific research, Mymetics has built a rich pipeline of vaccine candidates and valuable partnerships with leading research funding organizations.
Their innovative technology aims to prevent diseases by blocking viruses at the mucosal and serum level, offering a new generation of vaccines that could address the world's need for more preventive measures. From addressing highly contagious viruses like influenza and RSV to tackling major global health issues such as HIV/AIDS, malaria, and COVID-19, Mymetics is dedicated to advancing the field of virosome vaccines and improving public health worldwide.
Generated from the website